170 related articles for article (PubMed ID: 15910946)
1. Tobramycin dosing in cystic fibrosis.
Smyth A; Touw D; Tan KH; Bertenshaw C; Stableforth D
Lancet; 2005 May 21-27; 365(9473):1767-8. PubMed ID: 15910946
[No Abstract] [Full Text] [Related]
2. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?
Vandenbussche HL; Klepser ME
Lancet; 2005 Feb 12-18; 365(9459):547-8. PubMed ID: 15708080
[No Abstract] [Full Text] [Related]
3. Tobramycin inhalation solution (Bethkis) for cystic fibrosis.
Med Lett Drugs Ther; 2014 Jun; 56(1445):51-2. PubMed ID: 24956309
[No Abstract] [Full Text] [Related]
4. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial.
Smyth A; Tan KH; Hyman-Taylor P; Mulheran M; Lewis S; Stableforth D; Prof Knox A;
Lancet; 2005 Feb 12-18; 365(9459):573-8. PubMed ID: 15708100
[TBL] [Abstract][Full Text] [Related]
5. Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis.
Thomsen J; Friis B; Jensen K; Bak-Pedersen K; Larsen PK
J Antimicrob Chemother; 1979 May; 5(3):257-60. PubMed ID: 479061
[No Abstract] [Full Text] [Related]
6. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy.
Hoffmann IM; Rubin BK; Iskandar SS; Schechter MS; Nagaraj SK; Bitzan MM
Pediatr Pulmonol; 2002 Nov; 34(5):375-7. PubMed ID: 12357482
[TBL] [Abstract][Full Text] [Related]
7. Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
Med Lett Drugs Ther; 2013 Jun; 55(1419):51-2. PubMed ID: 23797798
[No Abstract] [Full Text] [Related]
8. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
[TBL] [Abstract][Full Text] [Related]
9. Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements.
Chuchalin A; Amelina E; Bianco F
Pulm Pharmacol Ther; 2009 Dec; 22(6):526-32. PubMed ID: 19616111
[TBL] [Abstract][Full Text] [Related]
10. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.
Mulheran M; Hyman-Taylor P; Tan KH; Lewis S; Stableforth D; Knox A; Smyth A
Antimicrob Agents Chemother; 2006 Jul; 50(7):2293-9. PubMed ID: 16801404
[TBL] [Abstract][Full Text] [Related]
11. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
12. Minimizing the toxicity of aminoglycosides in cystic fibrosis.
Smyth AR
J R Soc Med; 2010 Jul; 103 Suppl 1(Suppl 1):S3-5. PubMed ID: 20573667
[No Abstract] [Full Text] [Related]
13. Lack of concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis centers.
Tan KH; Hyman-Tylor P; Mulheran M; Knox A; Smyth A
Pediatr Pulmonol; 2002 Feb; 33(2):165. PubMed ID: 11802256
[No Abstract] [Full Text] [Related]
14. Parenteral administration of tobramycin for pulmonary exacerbations in cystic fibrosis patients: toxicity, serum levels and efficacy.
Braccini G; Lori I; Neri AS; Festini F; Pela I; Ciuti R; Boni V; Zavataro L; Braggion C; De Martino M; Taccetti G
J Chemother; 2009 Feb; 21(1):101-4. PubMed ID: 19297282
[No Abstract] [Full Text] [Related]
15. TOBI: reducing the impact of pseudomonal infection.
Govan J
Hosp Med; 2002 Jul; 63(7):421-5. PubMed ID: 12187603
[TBL] [Abstract][Full Text] [Related]
16. Skin contamination leading to falsely elevated fingerprick tobramycin levels in a patient taking dry powder inhaled tobramycin.
Barry PJ; Jones AM
J Cyst Fibros; 2014 Dec; 13(6):754. PubMed ID: 24795286
[No Abstract] [Full Text] [Related]
17. Tobramycin Inhalation Powderâ„¢: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
[TBL] [Abstract][Full Text] [Related]
19. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
[TBL] [Abstract][Full Text] [Related]
20. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial.
Ratjen F; Munck A; Kho P; Angyalosi G;
Thorax; 2010 Apr; 65(4):286-91. PubMed ID: 19996339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]